Zhengye Biotechnology Holding Ltd ZYBT

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022
Revenue $16.6M$25.5M——
Cost of revenue $13.2M$13.0M——
Gross profit $3.4M$12.5M——
R&D $2.6M$1.8M——
SG&A $4.4M$3.1M——
Total operating expenses $13.5M$10.3M——
Operating income -$10.1M$2.3M——
Interest expense $486.0K$554.0K——
Pre-tax income -$10.3M$2.0M——
Income tax $1.6M$127.0K——
Net income -$10.0M$1.6M——
EPS, basic —0.03——
EPS, diluted —0.03——
Shares, diluted (wtd. avg.) 47.3M45.7M45.7M45.7M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022
Cash and equivalents $7.2M$2.7M$3.7M—
Short-term investments $223.0K$197.0K——
Receivables $2.6M$8.2M——
Inventory $5.6M$8.0M——
Total current assets $19.6M$24.3M——
Property, plant and equipment $33.9M$35.0M——
Other intangibles $6.7M$2.0M——
Total assets $62.4M$67.6M——
Accounts payable $6.3M$5.9M——
Short-term debt $100.0K$985.0K——
Total current liabilities $17.2M$18.6M——
Long-term debt $1.4M$658.0K——
Total liabilities $18.6M$19.3M——
Retained earnings -$3.1M$6.6M——
Total equity $35.7M$38.9M——

Cash flow

Fiscal year FY2025FY2024FY2023FY2022
Operating cash flow $1.9M$5.6M——
Depreciation and amortisation $3.0M$2.8M——
Capital expenditure $144.0K$1.9M——
Investing cash flow -$1.8M-$3.8M——
Financing cash flow $4.6M-$3.0M——
Dividends paid —$2.2M——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-048584.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -10M 0 10M 20M 30M Revenue, FY2024: 25.5M Gross profit, FY2024: 12.5M Net income, FY2024: 1.6M Revenue, FY2025: 16.6M Gross profit, FY2025: 3.4M Net income, FY2025: -10M FY2022 FY2023 FY2024 FY2025
Fiscal year FY2022FY2023FY2024FY2025
Revenue — — $25.5M $16.6M
Gross profit — — $12.5M $3.4M
Net income — — $1.6M -$10.0M

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%